ROLE OF [-2]proPSA AND ITS DERIVATIVES IN PROSTATE CANCER SCREENING IN MEN WITH A TOTAL PROSTATE-SPECIFIC ANTIGEN LEVEL OF 2-10 NG/ML
Issue:
6
Year:
2015
The efficiency of using [-2]proPSA and its derivative a p2PSA to free prostatespecific antigen (PSA) ratio (%p2PSA) for the early detection of prostate cancer in men with a total prostate-specific antigen level of 2 to 10 ng/ml.
Keywords:
prostate cancer
[-2]proPSA
screening
References:
- Siddiqui M., Rais-Bahrami S., Turkbey B. et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer // JAMA. – 2015; 313 (4): 390–7.
- Siegel R., Naishadman D., Jemal A. Cancer statistics, 2013 // CA Cancer J. Clin. – 2013; 63 (1): 11–30.
- Schroder F., Hugosson J., Roobol M. et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up // Lancet. – 2014; 384 (9959): 2027–35.
- Le B., Griffin C., Loeb S. et al. [-2] Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study // J. Urol. – 2010; 183 (4): 1355–9.ROL